Sanofi’s BTK inhibitor Wayrilz has become the first drug in the class to be approved by the FDA for immune thrombocytopenia (ITP), a rare autoimmune blood disorder. Wayrilz (rilzabrutinib) has been cleared by the US regulator for adults with persistent or chronic ITP who have had an insufficient response to a previous treatment. In ITP,…
Sanofi Wayrilz wins USFDA approval for adults with immune thrombocytopenia We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Sanofi Rilzabrutinib earns orphan designation in EU for IgG4 related disease We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Rilzabrutinib reduces itch and hives in patients with chronic spontaneous urticaria: JAMA We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link